Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges.

Onco Targets Ther · 2019 · PMC6580132 · PMID 31354294

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

There was also a nonsignificant trend for improved OS in the phased ipilimumab arm (mOS 12.5 months, 95% CI 7.9–14.9), compared with mOSs of 9.1 months (95% CI 6.7–13.0) for the concurrent arm and 10.5 months (95% CI 8.6–11.7) for the control arm.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.